​

Celldex Therapeutics (CLDX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

CLDX Stock Forecast

Celldex Therapeutics (CLDX) stock forecast, based on 8 Wall Street analysts, predicts a 12-month average price target of $62.00, with a high of $80.00 and a low of $44.00. This represents a 143.04% increase from the last price of $25.51.

$25 $36 $47 $58 $69 $80 High: $80 Avg: $62 Low: $44 Last Closed Price: $25.51

CLDX Stock Rating

Celldex Therapeutics stock's rating consensus is Buy, based on 8 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (62.50%), 3 Hold (37.50%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 8 0 3 5 Strong Sell Sell Hold Buy Strong Buy

CLDX Forecast vs Benchmarks

TypeNameUpside
StockCelldex Therapeutics143.04%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts--3
Avg Price Target--$60.67
Last Closing Price$25.51$25.51$25.51
Upside/Downside--137.83%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 25192--12
Dec, 24192--12
Nov, 24193--13
Oct, 24593--17
Sep, 24583--16
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 29, 2024Joseph PantginisH.C. Wainwright$80.00$27.12194.99%213.60%
Sep 25, 2024Derek ArchilaWells Fargo$44.00$36.0222.15%72.48%
Jun 17, 2024Alex ThompsonStifel Nicolaus$58.00$34.9166.14%127.36%
Nov 10, 2023Derek ArchilaWells Fargo$27.00$25.784.73%5.84%
Nov 11, 2022Guggenheim$63.00$39.8957.93%146.96%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Jan 08, 2025CitigroupBuyBuyhold
Oct 29, 2024H.C. WainwrightBuyBuyhold
Oct 28, 2024Cowen & Co.BuyBuyhold
Oct 28, 2024Wolfe ResearchBuyBuyhold
Oct 28, 2024GuggenheimBuyBuyhold
Oct 07, 2024CitigroupBuyinitialise
Sep 30, 2024Goldman SachsNeutralinitialise
Sep 27, 2024Leerink PartnersMarket Performdowngrade
Sep 26, 2024Wolfe ResearchBuyPeer Performdowngrade
Sep 25, 2024GuggenheimBuyBuyhold

Financial Forecast

EPS Forecast

$-3K $-2K $-2K $-1K $-600 $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.02$-1.64$-2.62$-2.92K-----
Avg Forecast$-1.77$-1.64$-2.38$-2.80$-2.45$-3.28$-3.79$-3.75$-1.07
High Forecast$-3.21$-2.97$-3.71$-2.95$-2.59$-3.55$-4.82$-4.28$-1.74
Low Forecast$-0.91$-0.84$-1.61$-2.60$-2.35$-2.93$-2.85$-3.15$-0.61
Surprise %14.12%-10.08%104154.64%-----

Revenue Forecast

$0 $100M $200M $300M $400M $500M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$7.42M$4.65M$2.36M$6.88M-----
Avg Forecast$4.20M$5.34M$988.00K$4.11M$6.83M$4.00M$2.84M$51.13M$328.93M
High Forecast$2.63M$3.34M$742.71K$3.22M$5.67M$2.68M$2.82M$34.22M$220.10M
Low Forecast$6.82M$8.67M$1.41M$4.95M$8.32M$5.95M$2.85M$76.03M$489.11M
Surprise %76.62%-12.90%138.56%67.57%-----

Net Income Forecast

$-250M $-200M $-150M $-100M $-50M $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-59.78M$-70.51M$-122.78M$-141.43M-----
Avg Forecast$-85.92M$-79.46M$-86.68M$-141.43M$-119.81M$-157.14M$-185.74M$-180.08M$-51.60M
High Forecast$-155.65M$-143.95M$-104.02M$-169.71M$-125.56M$-172.12M$-233.39M$-207.53M$-84.26M
Low Forecast$-44.15M$-40.83M$-69.35M$-113.14M$-114.06M$-142.17M$-138.09M$-152.63M$-29.41M
Surprise %-30.42%-11.26%41.64%------

CLDX Forecast FAQ

Is Celldex Therapeutics stock a buy?

Celldex Therapeutics stock has a consensus rating of Buy, based on 8 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Celldex Therapeutics is a favorable investment for most analysts.

What is Celldex Therapeutics's price target?

Celldex Therapeutics's price target, set by 8 Wall Street analysts, averages $62 over the next 12 months. The price target range spans from $44 at the low end to $80 at the high end, suggesting a potential 143.04% change from the previous close price of $25.51.

How does Celldex Therapeutics stock forecast compare to the average forecast of its sector, industry, and investment themes?

Celldex Therapeutics stock forecast shows a 143.04% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and outperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for Celldex Therapeutics over the past three months?

  • January 2025: 8.33% Strong Buy, 75.00% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 8.33% Strong Buy, 75.00% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 7.69% Strong Buy, 69.23% Buy, 23.08% Hold, 0% Sell, 0% Strong Sell.

What is Celldex Therapeutics’s EPS forecast?

Celldex Therapeutics's average annual EPS forecast for its fiscal year ending in December is -2.45 for 2024, a -99.92% decrease from the reported $-2.919K in 2023. The prediction for 2025 is $-3.28, $-3.79 for 2026, $-3.75 for 2027, and $-1.07 for 2028.

What is Celldex Therapeutics’s revenue forecast?

Celldex Therapeutics's average annual revenue forecast for its fiscal year ending in December is $6.83M for 2024, a -0.78% decrease from the reported $6.88M in 2023. The forecast for 2025 is $4M, $2.84M for 2026, $51.13M for 2027, and $328.92M for 2028.

What is Celldex Therapeutics’s net income forecast?

For its fiscal year ending in December, Celldex Therapeutics's average annual net income forecast is $-120M for 2024, reflecting a -15.29% decrease from the reported $-141M in 2023. The projection for 2025 is $-157M, $-186M for 2026, $-180M for 2027, and $-51.598M for 2028.